Influenza Virus NP 91–99 (HLA-A*68:01) KTGGPIYKR

The Influenza A M1 125–132 epitope (amino acid sequence: ASCMGLIY) is a CD8⁺ T cell epitope derived from Matrix Protein 1 (M1) of the Influenza A virus (UniProt ID: P03485). This 8-mer linear peptide is located within the membrane-binding domain of M1 and is known to be presented on the HLA class I molecules HLA-B27 and HLA-B35. This epitope has been referenced under IEDB Epitope ID: 4349. Human cytotoxic T lymphocyte (CTL) responses to Influenza A virus are known to target multiple epitopes, with a dominant response frequently observed against the HLA-A2-restricted epitope M1 58–66. ASCMGLIY was used in a study that investigated the influence of HLA makeup on the overall CTL response against influenza viruses. CTL responses were analyzed in groups of individuals who shared identical HLA-A and HLA-B alleles, with each group having two or three of the same four alleles. [1; under Tab References] Following in vitro stimulation of PBMCs with influenza virus, the strongest CTL activity was observed in HLA-A2-positive donors. CTL activity and precursor frequency (CTLp) were assessed for specific influenza-derived epitopes. Notably, the CTLp frequency for the HLA-B8-restricted epitope NP 380–388 was found to be threefold lower in HLA-B27-positive individuals compared to HLA-B27-negative individuals. Importantly, a threefold increase in CTLp frequency for the HLA-A1-restricted epitope NP 44–52 was observed in individuals who were positive for HLA-A1, HLA-A2, HLA-B8, and HLA-B35. This elevated response was further confirmed by in vitro CTL assays. These results suggest that CTL epitope specificity is influenced not only by the presenting HLA allele, but also by the broader HLA-A and HLA-B genotype. Moreover, the overall strength of the CTL response to influenza appears to be modulated by an individual’s HLA phenotype, highlighting the immunological relevance of HLA-B27/B35-positive donors in the context of specific epitope responses.

The Influenza A M1 Peptide Pool is a carefully designed mix of 61 overlapping 15-mer peptides (11-amino-acid overlap) that span the full-length Matrix protein 1 (UniProt ID: P03485) of Influenza A virus. This peptide pool enables robust stimulation of influenza-specific CD4⁺ and CD8⁺ T cells in various immunomonitoring assays, including: ELISPOT   Intracellular cytokine staining (ICS)   Flow cytometry   Activation-Induced Marker (AIM) assays The peptide pool is suitable for infection models, vaccine evaluation, and cellular immune response profiling. One unit allows the stimulation of 2,5 x 108 cells. Key Features: Covers the entire M1 protein (252 amino acids) of Influenza A Virus Tested for endotoxin-free performance     Lyophilized, ready for reconstitution   Suitable for both in vitro stimulation and ex vivo detection of T cell responses Applications: Monitoring influenza-specific cellular immunity Evaluation of vaccine candidates or adjuvants Detection of memory T cell responses post-infection or vaccination Use in longitudinal studies or clinical immunology research Background Matrix protein 1 (M1) is the most abundant structural protein in Influenza A virions and plays a crucial role in multiple steps of the viral life cycle – from genome uncoating during host cell entry to assembly and budding. It forms a protein shell beneath the lipid envelope and mediates interactions with ribonucleoprotein complexes (vRNPs), membrane proteins, and the M2 ion channel. Due to its high conservation and immunogenicity, M1 is a well-established target for T cell-mediated immunity and a valuable component in vaccine and infection research.

The Influenza A NP 418–426 peptide (Sequence: LPFDKTTVM) is a linear peptidic epitope derived from the viral Nucleoprotein (NP, UniProt ID: P03466) of the Influenza A virus. It represents a well-known sequence variant of the canonical LPFDRTTVM epitope found in strain A/PR/8/1934 H1N1, making it an essential tool for investigating viral escape mechanisms, cross-reactive T-cell recognition, and strain-specific immune profiling.Restricted to HLA-B*07:02, this catalog peptide enables researchers to expand their HLA class I coverage beyond standard HLA-A alleles in viral immunomonitoring assays. Key Features & Applications Sequence Variant Insights: Features the K422 substitute relative to the PR8 reference strain (LPFDRTTVM), making it ideal for epitope variant analysis and T-cell receptor (TCR) cross-reactivity studies. Targeted HLA-B Restriction: Specifically restricted to HLA-B*07:02, a common MHC class I allele crucial for population-representative T-cell profiling (IEDB Epitope ID: 116124). Assay Compatibility: Validated for use in ELISpot, Intracellular Cytokine Staining (ICS), MHC multimer binding assays, and CTL activation experiments. Cross-Referenced Control Pools Looking for this epitope as part of a broader immune monitoring panel? This catalog peptide is also available as a core component in the following off-the-shelf peptides&elephants control pools: Influenza control Peptide Pool (>95% HPLC)CEF control Peptide Pool (>95% HPLC, advanced)

SDYEGRLI is a linear peptidic epitope (epitope ID57322) studied as part of Nucleoprotein from Influenza A virus. This epitope has been studied for immune reactivity, tested in T cell assays, B cell assay and MHC ligand assays

The Influenza A NP 342–351 peptide (Sequence: RVLSFIKGTK) is a versatile, conserved peptidic epitope derived from the viral Nucleoprotein (NP, UniProt ID: P03466) of the Influenza A virus. This epitope exhibits broad HLA coverage, with known restrictions across multiple HLA-A supertypes including HLA-A*03:01, HLA-A*31:01, and HLA-A*33:01. Its multi-allele binding capacity makes it an essential reagent for population-scale immunomonitoring, cross-reactive CD8+ T-cell profiling, and viral immunity research. Key Features & Applications Broad HLA Coverage: Recognized in the context of HLA-A*11:01, HLA-A*03:01, HLA-A*31:01, and HLA-A*33:01, offering wide applicability across diverse donor cohorts. Experimental Validation: Documented in 5 scientific publications and evaluated across 11 T-cell assays and 6 MHC ligand binding assays (IEDB Epitope ID: 56355). Assay Compatibility: Optimized for functional immune assays including ELISpot, Intracellular Cytokine Staining (ICS), MHC multimer analysis, and T-cell activation studies. Cross-Referenced Control Pools Looking for this epitope within a broader positive control panel? This catalog peptide is also available as a component in: Influenza control Peptide Pool (>95% HPLC)CEF control Peptide Pool (>95% HPLC, advanced)

ELRSRYWAI is a linear peptidic epitope (epitope ID13263) studied as part of Nucleoprotein from Influenza A virus. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

FMYSDFHFI is a linear peptidic epitope (epitope ID 17119) studied as part of Polymerase acidic protein (UniProt: P03433) and Polymerase basic protein 2 (UniProt: P03428) from Influenza A virus. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.Restrictions are known for:HLA-A*02:01HLA-A*02:02HLA-A*02:03HLA-A*02:06HLA-A*68:02 This catalog peptide is also available in the following off-the-shelf Control Pools:Influenza control Peptide Pool (>95% HPLC)CEF control Peptide Pool (>95% HPLC, advanced)